Literature DB >> 22078408

Surgical therapy for intermediate risk prostate cancer.

George R Schade1, David P Wood.   

Abstract

Optimal surgical management of intermediate risk prostate cancer has yet to be defined. This is in part due to the heterogeneity of the disease burden in this patient population. When choosing the surgical approach for intermediate risk prostate cancer, urologists should attempt to maximize oncologic outcomes while balancing quality of life concerns. Due to significant risk of failure following solo treatment, multi-modality therapy should be available for those patients with poor pathologic outcomes following surgical therapy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22078408     DOI: 10.1016/j.urolonc.2011.03.010

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  1 in total

1.  A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer.

Authors:  Shengsheng Zhu; Qinxia Wang; Juan Jiang; Yongwei Luo; Zuyue Sun
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.